IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 316 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,425 | +4.1% | 7,527 | -5.8% | 0.11% | +7.9% |
| Q2 2023 | $327,953 | +5.8% | 7,993 | -7.8% | 0.10% | +6.3% |
| Q1 2023 | $309,973 | +96464.8% | 8,673 | +2.0% | 0.10% | -7.8% |
| Q4 2022 | $321 | -99.9% | 8,499 | -3.8% | 0.10% | -22.0% |
| Q3 2022 | $391,000 | +10.5% | 8,833 | -7.5% | 0.13% | +20.0% |
| Q2 2022 | $354,000 | -1.7% | 9,551 | -1.7% | 0.11% | +14.6% |
| Q1 2022 | $360,000 | +42.3% | 9,714 | +16.8% | 0.10% | +52.4% |
| Q4 2021 | $253,000 | -26.9% | 8,318 | -19.4% | 0.06% | -30.0% |
| Q3 2021 | $346,000 | -18.0% | 10,324 | -2.4% | 0.09% | -17.4% |
| Q2 2021 | $422,000 | -10.8% | 10,583 | +0.7% | 0.11% | -16.8% |
| Q1 2021 | $473,000 | -20.6% | 10,512 | -0.4% | 0.13% | -24.7% |
| Q4 2020 | $596,000 | +13.1% | 10,549 | -5.0% | 0.17% | -1.7% |
| Q3 2020 | $527,000 | -21.3% | 11,101 | -2.3% | 0.18% | -28.9% |
| Q2 2020 | $670,000 | +12.6% | 11,365 | -9.7% | 0.25% | -6.0% |
| Q1 2020 | $595,000 | -33.6% | 12,582 | -15.1% | 0.26% | -5.7% |
| Q4 2019 | $896,000 | -5.3% | 14,828 | -6.1% | 0.28% | -9.9% |
| Q3 2019 | $946,000 | -9.9% | 15,798 | -3.3% | 0.31% | -7.7% |
| Q2 2019 | $1,050,000 | -19.5% | 16,338 | +1.6% | 0.34% | -21.4% |
| Q1 2019 | $1,305,000 | +46.5% | 16,083 | -2.4% | 0.43% | +36.1% |
| Q4 2018 | $891,000 | +2.5% | 16,486 | -2.1% | 0.32% | +14.1% |
| Q3 2018 | $869,000 | +24.1% | 16,847 | +0.2% | 0.28% | +17.9% |
| Q2 2018 | $700,000 | -11.1% | 16,807 | -5.9% | 0.24% | -10.6% |
| Q1 2018 | $787,000 | -11.6% | 17,860 | +1.0% | 0.26% | -10.5% |
| Q4 2017 | $890,000 | -4.5% | 17,688 | -3.8% | 0.29% | -6.7% |
| Q3 2017 | $932,000 | -1.4% | 18,378 | -1.1% | 0.32% | -4.5% |
| Q2 2017 | $945,000 | +30.3% | 18,577 | +3.1% | 0.33% | +23.6% |
| Q1 2017 | $725,000 | -12.5% | 18,024 | +4.0% | 0.27% | -16.6% |
| Q4 2016 | $829,000 | +75.3% | 17,328 | +34.3% | 0.32% | +73.0% |
| Q3 2016 | $473,000 | +55.6% | 12,898 | -1.0% | 0.18% | +48.0% |
| Q2 2016 | $304,000 | -39.7% | 13,034 | +4.8% | 0.12% | -44.4% |
| Q1 2016 | $504,000 | -28.7% | 12,440 | +9.0% | 0.22% | -33.8% |
| Q4 2015 | $707,000 | – | 11,414 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,046 | $126,557 | 6.89% |
| M28 Capital Management LP | 126,300 | $4,513,962 | 5.10% |
| Bellevue Group AG | 9,511,900 | $339,955,306 | 4.93% |
| Deep Track Capital, LP | 2,834,069 | $101,289,626 | 4.16% |
| BVF INC/IL | 2,560,761 | $91,521,598 | 3.35% |
| Sicart Associates LLC | 210,698 | $7,530,347 | 2.93% |
| Privium Fund Management B.V. | 182,773 | $6,532,307 | 2.19% |
| Camber Capital Management LP | 1,925,000 | $68,800 | 2.12% |
| Orbimed Advisors | 2,124,500 | $75,929,630 | 1.49% |
| SECTOR GAMMA AS | 146,441 | $5,233,801 | 1.27% |